Our investment solutions give institutional and qualified investors access to unlisted infrastructure investments in Switzerland and Europe. Besides first-class fund solutions and other collective investments, we develop and manage tailor-made infrastructure mandates for qualified investors.
Get to know us personally.
As part of a broad-based initiative to strengthen personal responsibility in the banking sector, a guest article entitled “Haften statt retten” (Liability instead of rescue) was published in the Neue Zürcher Zeitung (NZZ) on September 1, 2025. The article was written by Christian Bidermann, partner at Rahn & Bodmer and Jürg Staub, general partner at Reichmuth & Co.
Switzerland is sitting on a ticking currency time bomb: the Swiss franc. What has been regarded as a sign of stability and solidity for years could prove highly explosive in the event of a new global economic shock. While the Swiss Confederation shines as a safe haven with one of the lowest debt ratios in the world and a credible monetary stability policy pursued by the SNB, it is precisely this status that threatens to become a challenge.
The pharmaceutical industry is currently high on Donald Trump’s list of priorities. He wants more production and jobs in the US, as well as lower drug prices. As a means of exerting pressure, he is threatening to impose price caps and introduce tariffs on drugs. These goals are, of course, contradictory, which is causing even more uncertainty.